HGH Fragment 176-191 is a stabilized analogue of the GH region specifically responsible for fat metabolism, shown to have approximately 12.5x the lipolytic potency of full GH with no effect on IGF-1, insulin sensitivity, or anabolic signaling.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
HGH Fragment 176-191 is a stabilized analogue of amino acids 176–191 of the human growth hormone polypeptide chain — the specific region responsible for GH's fat-metabolizing properties. Researchers at Monash University discovered that this small fragment retains approximately 12.5 times the fat-burning potency of full GH while having no effect on insulin sensitivity or IGF-1 levels. It is considered a pure lipolytic peptide and is one of the most targeted fat-loss research compounds available.
Mechanism of Action
The 176–191 region of GH is the segment that interacts with lipid receptors on adipocytes and stimulates the enzyme hormone-sensitive lipase (HSL), which is responsible for breaking down stored triglycerides. Fragment 176-191 activates beta-3 adrenergic pathways and inhibits the action of lipoprotein lipase (LPL), the enzyme that promotes fat storage. It also appears to enhance fat oxidation in skeletal muscle via upregulation of mitochondrial fat-burning enzymes. Unlike full GH, the fragment does not activate insulin-like signaling or promote glucose uptake in muscle — meaning it does not cause insulin resistance or impact carbohydrate metabolism. This clean separation of the anabolic and lipolytic effects of GH makes it uniquely valuable for isolated fat loss research.
Key Research
HGH Fragment 176-191 was identified through systematic truncation studies of the GH molecule by Monash University researchers seeking to isolate the lipolytic domain without anabolic effects. Preclinical studies demonstrated it achieves approximately 12.5x the fat-burning potency of full GH, measured by lipolysis assays. Animal studies confirmed no effect on IGF-1 levels, no insulin resistance, and no effect on longitudinal bone growth — validating the separation of GH's lipolytic and somatogenic activities. Multiple in vitro and in vivo studies established its mechanism via beta-3 adrenergic receptor activation and HSL stimulation. Phase I human clinical trials confirmed safety without metabolic side effects.
Typical research dosing is 250–500 mcg per day, administered subcutaneously. For maximum lipolytic effect, it should always be injected in a fasted state — either first thing in the morning before eating or before a fasted workout — as elevated insulin virtually eliminates its efficacy. A common approach is 250 mcg in the morning (fasted) and 250 mcg in the early afternoon (3–4 hours after lunch). Some protocols use a single 500 mcg morning dose. Cycle length is typically 8–16 weeks. It is frequently combined with a dietary protocol emphasizing intermittent fasting or low-carbohydrate eating to maximize the fasted window when the peptide is active.
Classic Fat Loss Protocol: HGH Fragment 176-191 250 mcg injected morning (fasted) + 250 mcg mid-afternoon for 12 weeks. Combined Peptide Fat Loss Stack: Frag 176-191 500 mcg/day + AOD-9604 300 mcg/day + CJC-1295/Ipamorelin 100/200 mcg at bedtime for comprehensive GH-related lipolysis. Best results in research when combined with a low-carbohydrate or intermittent fasting dietary model.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
HGH Fragment 176-191 has a remarkably clean safety profile. The most common report is mild hypoglycemia — lightheadedness, mild shakiness — if injected and the subject then eats a carbohydrate-heavy meal too quickly after. This is not due to insulin resistance but to the surge in fat oxidation temporarily displacing glucose as the primary fuel. Injection site redness or mild pain is occasionally reported. Unlike full GH, there is no water retention, no joint pain, no acromegaly risk, and no suppression of endogenous GH or IGF-1. Fatigue can occasionally be reported after the dose, consistent with the metabolic shift to fat oxidation.
Storage & Handling
Store lyophilized HGH Fragment 176-191 at 2–8°C, protected from light. Stable for 12–18 months in lyophilized form. Reconstitute with bacteriostatic water; a 5 mg vial with 2.5 mL BAC water yields 2,000 mcg/mL. Store reconstituted solution at 2–8°C and use within 28 days. The peptide is relatively fragile — avoid repeated freezing and thawing, temperature fluctuations, and vortex mixing (gently swirl or roll the vial to dissolve).
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
